Skip to main content

Table 1 Demographic and clinical characteristics of the asthma group and normal control groups

From: Expression levels of plasma exosomal miR-124, miR-125b, miR-133b, miR-130a and miR-125b-1-3p in severe asthma patients and normal individuals with emphasis on inflammatory factors

  Control (n = 30) Severe asthma (n = 30) P-value
Age 39.23 ± 10.17 42.13 ± 9.41 0.26
Sex (M/F) 13/17(43.3/56.7%) 12/18 (40/60%)
Age of asthma onset (Year) 31.90 ± 10.55  
FEV1 (% predicted) ± SD 99.19 ± 10.99 51.37 ± 16.10  < 0.0001
FVC (% predicted) ± SD 94.02 ± 8.39 63.50 ± 14.84  < 0.0001
FEV1/FVC 0.85 ± 0.59 0.69 ± 0.11  < 0.0001
BMI (Mean ± SD) 22.46 ± 2.28 23.30 ± 2.04 0.14
Blood eosinophil X 109 per L 0.09 ± 0.04 0.52 ± 0.21  < 0.0001
Medication requirements (n)
ICS(LABA and LAMA) / ICS + OCS
10/20
Atopic (%) Non 80.0 (n = 24)
Serum IgE IU/mL 39.32 ± 5.33 232.8 ± 25.79  < 0.0001
  1. Asthma patients were divided into two groups according to the type of medication. One group was under Inhaled corticosteroid (ICS) and the other group was under ICS + Oral corticosteroid (OCS) therapy
  2. Normal controls had no history of predisposing to any chronic or inflammatory disease. Forced expiratory volume in 1 s (FEV1%) and Forced vital capacity (FVC %) detected. Atopic Determined by allergen skin prick tests. The p-value < 0.05 is considered significant